Objective
to compare the 3-year clinical outcomes treatment of CAD with dual-therapy CD34 antibody-covered SES (COMBO) or sirolimus-eluting stent (ORSIRO)
Study
multicentre, single-blind, non-inferiority, randomised trial
Population
all-comers
Endpoints
target lesion failure as composite of cardiac death, MI or target lesion revascularisation within 3 years
Conclusion
the ORSIRO stent was superior to the COMBO stent during the 3-year follow-up period mainly due to increased incidence of revascularisation in the first year after implantation of COMBO stent
Jakobsen et al. EuroIntervention 2023; online